Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Lim

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Future Oncology (London, England)|August 18, 2018
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III studyJin Li, Ruihua Xu, Shukui Qin, et al.
The New England Journal of Medicine|April 3, 2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancerEric Van Cutsem, Claus-Henning Köhne, Erika Hitre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patientsHans-Joachim Schmoll, Thomas Cartwright, Josep Tabernero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2013
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trialAlfredo Carrato, Anna Swieboda-Sadlej, Marzanna Staszewska-Skurczynska, et al.
Surgical Endoscopy|February 10, 2025
SAGES guidelines update to laparoscopy in the era of COVID-19Sunjay S Kumar, Elisa C Calabrese, Bethany J Slater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignanciesChiung-Ing Wong, Tong-San Koh, Ross Soo, et al.
Plos One|February 6, 2013
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patientsLing-Zhi Wang, Jacqueline Ramírez, Winnie Yeo, et al.
Surgical Endoscopy|September 28, 2021
Guidelines for the performance of minimally invasive splenectomyTammy L Kindel, Rebecca C Dirks, Amelia T Collings, et al.
Journal of Translational Medicine|April 19, 2015
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenibAndrea Li Ann Wong, Joline Si Jing Lim, Arvind Sinha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research GroupWinnie Yeo, Hyun C Chung, Stephen L Chan, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Future Oncology (London, England)|August 18, 2018
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III studyJin Li, Ruihua Xu, Shukui Qin, et al.
The New England Journal of Medicine|April 3, 2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancerEric Van Cutsem, Claus-Henning Köhne, Erika Hitre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patientsHans-Joachim Schmoll, Thomas Cartwright, Josep Tabernero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2013
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trialAlfredo Carrato, Anna Swieboda-Sadlej, Marzanna Staszewska-Skurczynska, et al.
Surgical Endoscopy|February 10, 2025
SAGES guidelines update to laparoscopy in the era of COVID-19Sunjay S Kumar, Elisa C Calabrese, Bethany J Slater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignanciesChiung-Ing Wong, Tong-San Koh, Ross Soo, et al.
Plos One|February 6, 2013
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patientsLing-Zhi Wang, Jacqueline Ramírez, Winnie Yeo, et al.
Surgical Endoscopy|September 28, 2021
Guidelines for the performance of minimally invasive splenectomyTammy L Kindel, Rebecca C Dirks, Amelia T Collings, et al.
Journal of Translational Medicine|April 19, 2015
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenibAndrea Li Ann Wong, Joline Si Jing Lim, Arvind Sinha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research GroupWinnie Yeo, Hyun C Chung, Stephen L Chan, et al.
Pageof 7